Wolfe sees ‘clear path’ to upside, starts Twist Bioscience at Outperform

As previously reported, Wolfe Research initiated coverage of Twist Bioscience (TWST) with an Outperform rating and $60 price target Twist, which has built a novel platform to industrialize DNA synthesis for increasingly rapid production of longer, customizable, and higher-quality DNA fragments “written” onto a silicon chip, has about 10,000-times the scale than traditional approaches, the analyst tells investors. In 2025, Twist’s growth rate is expected to be double that of the peer group and the firm sees “a clear path to revenue and margin upside,” the analyst added.